We are live on ! Find out more
VIRS

Pacer BioThreat Strategy ETF
VIRS

Delisted

VIRS was delisted on the 10th of October, 2024.

Back to rankings

4 hedge funds and large institutions have $1.12M invested in Pacer BioThreat Strategy ETF in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

13.97% less ownership

Funds ownership: 43.6% → 29.63% (-14%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

52% less capital invested

Capital invested by funds: $2.32M → $1.12M (-$1.2M)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$346K
2
UBS Group
UBS Group
Switzerland
+$114K

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$1.28M
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$358K

VIRS Hedge Fund Activity: Q3 2022 in Review

4 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q3 2022, worth a combined $1.12M — down 52% from $2.32M a quarter earlier.

Fund positioning in VIRS was balanced in Q3 2022: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $346K. The largest seller was Osaic Holdings, cutting an estimated $1.28M.

  • 4 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $1.12M of Pacer BioThreat Strategy ETF stock for Q3 2022, down 52% quarter-over-quarter.
  • 1 fund opened new Pacer BioThreat Strategy ETF positions in Q3 2022 and 1 closed out, a net change of 0 holders.
  • The largest Pacer BioThreat Strategy ETF buyer in Q3 2022 was Susquehanna International Group, an estimated $346K added.
  • The largest Pacer BioThreat Strategy ETF seller in Q3 2022 was Osaic Holdings, an estimated $1.28M sold.

Based on aggregated 13F filings for Q3 2022.